Sanofi

Sanofi-aventis

Sanofi-synthelabo

Other

Societe Anonyme: Elf Sanofi

Pascual Ferrara

Daniel Caput

Natalio Vita

Patrick Laurent

Pascal Leplatois

Mourad Kaghad

Jean-Claude Guillemot

Marc Louis Salome

Richard Legoux

Ahmed Mourad Kaghad

Johannes Lupker

Elisabeth Larbre

Adrian Minty

Pascale Chalon

Didier Van Broeck

Gerard Loison

Raymond Paul

Alain Bayol

Jean C Breliere

Martine Laporte

Willem Roskam, Deceased

Jorge Rosenfeld

Thierry Maureaud

Genevieve Perry

G Erard Loison

Marilyn Magazin

Christine Labit-Le Bouteiller

Christine Lebouteiller

Bertrand Basuyaux

Brigitte Miloux

This invention relates to monoclonal and polyclonal antibodies capable of specifically recognizing IL-13 receptor &#x3b1; and uses thereof.

IL-13 receptor antibodies

This invention relates to a purified polypeptide comprising an amino acid sequence chosen from the sequence SEQ ID NO:4 or biologically active amino acid sequences derived from SEQ ID NO:4.

Purified polypeptides having IL-13 receptor activity

The invention relates to new nucleic acid sequences of the family of tumor-suppressing genes related to the gene for the p53 protein, and to corresponding protein sequences.

Purified SR-p70 protein

The invention relates to new nucleic acid sequences of the family of tumour-suppressing genes related to the gene for the p53 protein, and to the corresponding protein sequences.

This invention relates to a purified polypeptide which constitutes the type-2 neurotensin receptor (NT-R2), as well as the nucleotide sequence encoding this polypeptide.

Type-2 neurotensin receptor (NT-R2)

The present invention relates to the use of compounds capable of displacing tritiated cis-N-cyclohexyl-N-ethyl &lsqb;3-(3-chloro-4-cyclohexylphenyl)-allyl&rsqb;amine from its receptors for the preparation of pharmaceutical compositions intended to combat cell proliferation.

Use of amines to produce drugs for preventing tumor cell proliferation

Chemokine NC28 (monocyte chemotactic protein-3, MCP-3) polypeptides and

The subject of the present invention is a protein having cytokine type activity, or a precursor of this protein, which comprises the following amino acid sequence (a1): ##STR1## in which Xaa represents Asp or Gly.

Protein having interleukin 13 activity, recombinant DNA coding for this

The invention concerns a new urate oxidase activity protein which has the following sequence (SEQ ID NO:1): ##STR1## optionally preceded by a methionine, or in that it may present a degree of substantial homology with this sequence. The invention is also aimed at medicines containing this protein as well as the genetic engineering implements to obtain it.

Urate oxidase activity protein, recombinant gene coding therefor,

An interleukin-2 preparation suitable for pharmaceutical purposes, consisting essentially of disialilated glycosylated interleukin-2, monosialilated glycosylated interleukin-2, or a mixture thereof, and substantially free of organic solvents, is isolated from recombinant CHO cells transformed with a vector containing a DNA sequence coding for a natural precursor of human interleukin-2, and is purified by a multi-step process.

Drugs containing a glycosylated interleukin-2

Growing community of inventors

Avignonet Lauragais, France

Pascual Ferrara